How to approach patients in relapse

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Pujade Lauraine, E ^a  

^a HÔTEL DIEU   (France)

Author keywords

Chemotherapy; Ovarian cancer; Relapse; Target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CANFOSFAMIDE; CARBOPLATIN; DOXORUBICIN; FARLETUZUMAB; FOLATE RECEPTOR 1; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NINTEDANIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM COMPLEX; PROTEIN KINASE B; TOPOTECAN; TRABECTEDIN; TREOSULFAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINTAFOLIDE;

ALOPECIA; ANTIGEN FUNCTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; CYTOREDUCTIVE SURGERY; DISEASE MARKER; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; HOMOLOGOUS RECOMBINATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHY; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RECURRENT CANCER; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

EID: 84866744738     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds358     Document Type: Article

References (24)

1. Friedlander M, Trimble E, Tinker A et al. Gynecologic Cancer InterGroup. Clinical trials in recurrent ovrian cancer. Int J Gynecol Cancer 2011; 21(4): 771-775.
2. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
3. Pujade-Lauraine E, Paraiso D, Cure H et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002; 21 (Abstr 829).
4. Rustin GJ, Quinn M, Thigpen T et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004; 96(6): 487-488.
5. Rustin GJ, van der Burg ME, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376 (9747): 1155-1163.
6. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13(12): 1702-1710.
7. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112(1): 265-274.
8. Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21(2): 289-295.
9. Bhosale P, Peungjesada S, Wei W et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 2010; 20: 936-934.
10. Sehouli J, Meier W, Wimberger P et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). J Clin Oncol 2012; 30 (suppl) (Abstr 5031).
11. Pujade-Lauraine E, Alexandre J. Update of randomized trials in recurrent disease. Ann Oncol. 2011; 22 (Suppl 8): viii61-viii64.
12. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28 (20): 3323-3329.
13. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28 (19): 3107-3114.
14. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30(17): 2039-2045.
15. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012; 30 (suppl) (Abstr LBA5002).
16. Oza AM, Cibula D, Oaknin A et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinumsensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol 2012; 30 (suppl) (Abstr 5001).
17. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase ii study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-1202.
18. Ten Bokkel Huinink W, Lane SR, Ross GA. International topotecan study group. Long-term survival in a phase iii, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-103.
19. Gordon AN, Tonda M, Sun S et al. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95: 1-8.
20. O'Byrne KJ, Bliss P, Graham JD et al. A phase iii study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [abstract 808]. Proc Am Soc Clin Oncol 2002; 21: 203a.
21. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinumresistant ovarian cancer. J Clin Oncol 2008; 26: 890-896.
22. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 25 (19): 2811-2818.
23. Meier W, du Bois A, Reuss A et al. Topotecan versus treosulphan in early recurrent ovarian cancer after primary platinum/paclitaxel chemotherapy. A prospective randomized phase III trial of the AGO ovarian cancer study group [abstract 005]. Int J Gynecol Cancer 2004; 14 (suppl 1): 2.
24. Vergote I, Finkler N, del Campo J et al. ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009; 45 (13): 2324-2332.